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Abstract 
The current work was carried out at InnoCore Pharmaceuticals and aimed at studying the 
production of implants by hot melt extrusion with controlled biphasic release as well the 
parameters influencing drug release kinetics. 
Hot melt extrusion is a suitable process to produce implants with biphasic release kinetics as 
we were able to fulfill essential requirements such as size and good physical integrity. By 
changing the polymer from PDL 02 to PDL 05 an increase in the burst release was noticed 
while the presence of glycolide, a monomer that decreases polymer hydrophobicity, leads to 
a shorter lag phase. The state of the protein also influences the release kinetics, for non-
stabilized protein the burst release is higher when compared with stabilized proteins.  The 
implant diameter did not have an influence on the drug release profile.  
The accumulation of acidic degradation products inside of the implant is crucial to obtain a bi-
phasic drug release. For this study, the protein used denatured during release, the 
accumulation of degradation products inside of the implant leaded to an acidic micro-
environment which is detrimental for the protein. At that low pH the protein loses the native 
conformation leading to a loss in the activity. Therefore, drugs which are highly sensitive to 
acidic environments seem not to be suitable for such therapeutic approach.  
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Resumo 
O presente trabalho foi desenvolvido na InnoCore Pharmaceuticals e tinha como objectivo a 
produção de implantes através de extrusão com uma libertação bifásica de proteína assim 
como, estudar quais os parâmetros que influenciam a cinética de libertação do composto 
activo utilizado. 
A extrusão é um método que permite a produção de implantes com libertação bifásica. A 
utilização do polímero PDL 05 em vez de PDL 02 faz com que exista um aumento no burst 
release enquanto que a presença de Ácido Glicólico, um monómero que diminui a 
hidrofobicidade do polímero, origina uma cinética de libertação com um menor período sem 
libertação de proteína. O uso de proteína estabilizada em inulina origina uma libertação com 
um menor burst release. Diferenças no diâmetro dos implantes não origina diferenças na 
cinética de libertação. 
A acumulação de produtos de degradação do polímero no interior do implante é crucial para 
obter a libertação bifásica pretendida. Contudo, para princípios activos sensíveis a pH acídicos 
este não é um método de tratamento adequado uma vez que, a acumulação de compostos 
acídicos origina uma diminuição brusca de pH que faz com que a proteína perca a sua 
conformação nativa perdendo também  atividade terapêutica. 
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1. Introduction 
1.1. Background and Project Presentation 
In the past few years the pharmaceutical industry developed a wide variety of new and more 
potent and specific drugs to treat different kinds of diseases. When a patient suffers from a 
chronic disease, usually repetitive dosages of medications for a long time have to be taken 
for treatment. Currently, alternative ways to deliver medicines are being created by 
developing controlled release drug loaded depot formulations. Controlled drug delivery 
formulations are usually based on polymeric micro and nanospheres, implants and pellets. 
These systems have been developed to address many difficulties associated with traditional 
drug administration methods. One of the major advantages offered by these systems is the 
capacity to protect sensitive bioactives such as proteins, which can easily be destroyed in the 
body because they are highly susceptible to changes of pH and, therefore, can easily lose 
their activity. Additionally, drug delivery systems can provide a constant drug level at the site 
of action, preventing peak-valley fluctuations and avoiding side effects. Finally, controlled 
drug delivery systems are usually designed in such a way that the number of administrations 
gets significantly reduced aiming at improving patient compliance. 
In very specific therapeutic circumstances the standard progressive drug release from 
polymeric systems is not recommended. Instead, such circumstances require the release of 
the appropriate drug after a lag time and the same drug must not be released at all during 
the initial phase of dosage form administration which can be a challenge when designing an 
appropriate delivery system. Pulsatile release systems can be classified in multiple-pulse and 
single-pulse systems. These systems are frequently based on polymeric materials that release 
a drug almost instantly after the lag phase. Different delivery systems have been developed 
such as microchip-based devices to release a large number of drugs according to a 
preprogrammed time pattern. They have the ability to release a multitude of individual doses 
of one or even several substances from a multitude of drug reservoirs. Since each individual 
dose have a pulsatile release, combining the release profile of each individual dose can 
generate any desirable release profile. Although, this technology is limited in terms of 
controlling release kinetics and has some disadvantages such as the limited amount of drug 
that can be release from an individual reservoir and the lack of degradability in a biological 
system. Pulsatile delivery systems are usually based on polymeric materials that release a 
drug rather abruptly. The development of biodegradable implants seems to be a good 
approach to have a biodegradable, pulsatile drug delivery system that can offer alternative 
release timings according to rational modifications applied to the polymer composition. 
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A better understanding of the influence of the polymer, drug properties and processing 
parameters on the drug release profiles from implants can improve the formulation of an 
implant drug delivery system by inducing a desirable, controllable and predictable drug 
release profile. 
Due to the confidentiality restrictions, the real name of the protein used cannot be disclosed. 
To preserve the identity of the protein of interest, which is hydrophilic and has around 45 
kDa, from now it will be called protein X. 
The objective of this work was to develop implants as a drug delivery system and study the 
effect of several process parameters such as drug loading, polymer composition and the state 
of the protein to be released from implants. One model protein was used and three states of 
that protein were analyzed: non-stabilized protein usually referred as coarse protein and 
stabilized protein using inulin prepared either by freeze drying or spray drying. The 
optimization of such therapeutic formulation aims at creating a bi-phasic release profile as 
represented in Figure 1. During an initial period a significant burst release should occur, 
followed by a lag phase where no protein is released and finally a second release period 
should be obtained where the rest of the bioactive molecule will be released from the 
implant. To achieve such desired release profile the characteristics of the polymers used will 
be crucial as hereafter discussed.  
 
Figure 1. Schematic representation of a bi-phasic release kinetics. 
1.2. Company presentation 
InnoCore Pharmaceuticals is a privately owned biopharmaceutical company that specializes in 
the production of drug delivery devices. It was founded in 2003, based in Groningen in The 
Netherlands. 
The core activities of InnoCore center on using a line of patented bioresorbable polymers 
named SynBiosys™ and SynBiosys Pro™ for drug delivery systems. These multi-block co-
polymers are used for controlled release of small molecules, peptides and proteins. Drug 
delivery formulations developed by InnoCore include injectable solid implants, microspheres, 
drug eluting coating and injectable hydrogels. The focus of the activities performed lays 
mostly on R&D and pre-clinical trials, but InnoCore is gaining more experience on clinical 
trials as their products are increasingly used for commercial goals. 
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1.3. Work Contributes 
The current project has helped InnoCore Pharmaceuticals to understand and characterize 
critical formulation parameters for the development of implants with a biphasic release 
profile. Problems associated to the effect of hot melt extrusion in the stability of proteins and 
the characteristics of polymers that can be applied successfully to the formulation process 
giving rise to a bi-phasic release will be addressed. Additionally, InnoCore Pharmaceuticals 
wants to understand whether their own platform of polymers (SynBioSys) offer advantages 
for such therapeutic application over standard PDLG and PDL polymers. By further 
understanding potential limitations on the process and potential competitive advantages, 
InnoCore Pharmaceuticals is going to get relevant technical information which can be crucial 
to decide about the future perspectives of the ongoing research about bi-phasic release from 
implants.  
1.4. Thesis organization 
The current chapter initiates the report of the project contextualizing and describing the 
motivation and main goals for the development of this work. Furthermore, Chapter 1 serves 
as a guideline to the overall work presented in the further chapters. In addition to 
Introduction, this work comprises six main chapters. 
In Chapter 2 (State of the art) a short review of current achievements in the field is provided. 
The potential of drug delivery systems, the importance of polymers in drug delivery systems 
and the mechanisms of drug release from those devices are presented. The potential of hot 
melt extrusion for pharmaceutical applications is also discussed. The importance of protein 
stabilization in sugars as well the suitable sugars for that are examined. 
In the section Materials and Methods (Chapter 3), a detailed description of the techniques is 
reported, including information about essential commercial products used. Materials and 
Methods are divided in 6 main sub-chapters. Fundamental techniques broadly used and/or 
representing key steps in the context of this work, have a short theoretical introduction 
previous to the detailed technical description. 
Chapter 4 (Results and Discussion) gives the results and the main conclusions and probable 
indications that can be perceived from the results shown and possible interpretations for the 
results are explained. 
Finally, Chapter 5 (Conclusions) gives an overview of the main findings, which reflect the 
novelty of the work presented. Additionally, future perspectives and recommendations are 
also discussed. 
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2. State of the Art 
2.1. Drug Delivery Systems 
Drug delivery systems may assume many alternative shapes and usually comprise the 
administration of an active pharmaceutical ingredient (API) to achieve better therapeutic 
effects or to reduce administration frequency. The latest advances and current challenges in 
drug delivery technology aim at providing the following benefits (1): 
- Controlled delivery rate of the therapeutic agent; 
- Maintenance of drug concentration in an optimal therapeutic range; 
- Maximization of efficacy-dose relationship; 
- Minimization of the needs for frequent dose intake; 
- Enhancement of patient compliance. 
Positive pharmacological properties of APIs may not be enough to trigger the desired 
biological effect as the molecule by itself needs to target and get internalized at the desired 
site of action. Thus, specific delivery mechanisms are often designed to promote controlled 
release and active targeting of encapsulated drugs, which ultimately improves therapeutic 
effects and also reduces potential toxic effects (2). In some cases, poor bioavailability, high 
toxicity, or simply the difficulty of targeting specific drugs to the desired body region make it 
impossible to use such a drug that otherwise would be considered a good therapeutic 
candidate. Therefore, the use of encapsulated drugs over traditional free drug administration 
may help overcoming these limitations (3). Furthermore, prolonged drug release would 
naturally give rise to less frequent dosing schedules which gets an increased importance in 
underdeveloped countries where poor patient compliance is often pointed out as major 
reason leading to treatment failure when fighting infectious diseases (4).  
In order to promote a controlled delivery of bioactive agents, following rates and 
concentrations that maximize the therapeutic effect without exceeding limits of toxicity, 
specialists in the field of delivery systems have been testing an endless number of techniques 
and materials, such as metals and natural or synthetics polymers. The progress of 
biomaterials has been crucial for the advancement of drug delivery technology as they are 
the key elements who provide tunable release of both hydrophilic and hydrophobic drugs (5). 
Although there are several parameters that may influence the final therapeutic outcome, the 
route of drug administration is possibly the most significant. Mechanisms of drug 
encapsulation and delivery have been designed in diverse shapes and formats, depending on 
the specificities of the API and disease in consideration (2). For instance, nanoparticles (NPs) 
due to their small size and ability to cross biological barriers are suitable for systemic 
administration (6). On the other hand, bigger particles in the range of 1-5 µm (microparticles 
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– MPs), owing to their higher density are often considered the ideal option for pulmonary 
drug delivery as they easily get deposited at the deep lung (7). Alternatively, implants have 
been considered for prolonged subcutaneous drug release (8). 
2.2 Polymers in Drug Delivery Systems 
Biodegradable polymers are receiving increasing attention for their use in a wide variety of 
medical and pharmaceutical applications. The use of synthetic polymer-based materials may 
provide considerable improvements in medical applications due to their thermal and 
mechanical properties and their natural decomposition into non-toxic products that are easily 
metabolized or excreted by the human body (9). The use of aliphatic polyesters have a 
leading position since hydrolytic and/or enzymatic chain cleavage yields hydroxy carboxylic 
acids, which in most cases are ultimately metabolized (10). The most common synthetic 
biodegradable polymers used in medical applications are polylactide, polyglycolide, and 
poly(ε-caprolactone). Final polymer key properties, namely degradation rate, tensile 
properties and surface chemical composition, can be optimized by copolymerization or 
blending of homo- and/or copolymers. 
2.2.1. SynBiosys Polymers 
InnoCore Pharmaceuticals owns a patented polymer platform called Synbiosys, which consists 
of biodegradable multiblock copolymers (MBCPs) prepared by chain-extension of pre-
polymers that incorporate D,L-lactide (L), glycolide (G), polyethylene glycol (PEG) (P) and ε -
caprolactone (C). By varying the length and monomer content of the building blocks several 
properties can be adjusted, such as glass transition temperature, hydrophobicity, swelling 
ratio, permeability and degradation rate.  
 
Figure 2. Schematic representation of the molecular structure of a SynBiosys polymer. 
The main attributes of SynBiosys polymers are present in Table 1. 
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Table 1. Key attributes of SynBiosys multi-block polymers. 
SynBiosys multiblock copolymers present improved characteristics when compared to 
commonly used biodegradable polymers, namely improved thermal, mechanical and 
processing characteristics. When a multiblock copolymer is composed of lactide, glycolide 
and/or ε-caprolactone segments, the polymer absorbs small amounts of water and, 
consequently, is characterized as non-swellable polymer. On the other hand, when PEG is 
introduced in one of the pre-polymers, it becomes possible to obtain polymers with higher 
hydrophilicity since they would be composed of a water swellable segment combined with 
other more hydrophobic, non-swellable segment. Playing with the composition and content of 
both hydrophilic and hydrophobic segments the polymer swelling degree and degradation 
rate can be controlled, being possible to manipulate drug release kinetics. This control over 
the copolymer properties is the most interesting characteristic of the SynBiosys platform. 
2.2.2. Polymer degradation 
The polymer chains can be degraded by two principal ways: chemical hydrolysis and 
enzymatic reaction. Many of the synthetic polyesters used in medical or pharmaceutical 
applications degrade mainly by pure hydrolysis, thus, polymer swelling degree due to water 
absorption provides a major influence in terms of degradation kinetics (11). 
The rate of degradation of a polymer may additionally be influenced by several other factors 
like the type of chemical bond in the polymer back-bone, hydrophobicity, molecular weight, 
crystallinity, copolymer composition and the presence of low molecular weight compounds 
(12). During the process of polymeric degradation, the loss of mechanical stability should be 
carefully analyzed since when it occurs too fast high concentrations of degradation products 
may accumulate leading to undesirable local toxicity (13). As any biodegradable polymer 
Precise delivery of small molecules, peptides and proteins 
Controllable release profiles (from days to months) 
Drug loading of 1 to 50 wt% 
Biocompatible and regulatory approved building blocks 
Completely bioresorbable with adjustable degradation rates 
Drug integrity and bioactivity preserved 
Low temperature processibility 
Patent protected 
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contains hydrolysable bonds, the specific degradation rate will always depend on the type 
and stability of chemical bond between monomers. For example, polymers containing 
anhydride or ortho-ester bonds are the most reactive ones with a faster rate of degradation. 
The ester bonds will degrade slower and carbonates offer good resistance to hydrolysis (13). 
The hydrolysis of the polymer bonds produces monomers and oligomers. Such degradation 
products, if small enough, will diffuse to the outside of the polymer block once the cleavage 
process has ended – a mechanism usually described as polymer erosion, which consists on 
the sequential loss of mass from degradable polymer matrices. Figure 3 shows the general 
mechanism of polymer erosion. In brief, the polymer chains will first degrade into monomers 
and oligomers and then they will dissolve and diffuse into the environment (14). 
 
Figure 3. Schematic representation of the mechanism of polymer erosion (14). 
In general terms, polymeric devices can degrade via one of two alternative mechanisms (15). 
They can either degrade via bulk erosion or surface erosion. This last consists on an outside-
in degradation process, where the environment will initially affect the surface until the 
polymer is completely degraded. Bulk erosion and degradation occurs when the polymer 
device degrades homogeneously over time as represented in Figure 4. If the water uptake by 
the polymer matrix is faster than polymer degradation, bulk degradation takes place due to 
uniform hydrolysis. However, several studies show a heterogeneous degradation mechanism. 
The degradation products generated inside of the polymeric device autocatalytically 
accelerate the degradation process due to an increase in the amount of carboxylic acid end 
groups which are responsible for the faster degradation in the center of the device when 
comparing to the surface (16).  On the other hand, if degradation is faster than the water 
ingress, hydrolysis will only occur at the edges and the polymer will be subjected to surface 
erosion (15). The degradation mechanism is usually influenced by the hydrophobicity of the 
polymer as a hydrophobic polymer matrix will probably cause surface degradation and a more 
hydrophilic polymer matrix will probably be faster degraded via bulk erosion (12). 
Biphasic Controlled Release of API’s from Biodegradable Implants 
State of the art 8 
 
Figure 4. Schematic representation of surface erosion versus bulk erosion (15). 
In addition, bulk and surface degradation differ in terms of rate profile. Ideally, bulk 
degradation has a linear degradation curve due to the homogenous degradation and surface 
degradation has a logarithmic degradation curve due to a decreasing surface area over time. 
Most models describe a single mechanism to produce quantitative predictions on degradation, 
but these models represent an idealization of reality. In practice, both mechanisms occur at 
the same time (15). 
2.2.3. Mechanisms of Drug Release from Polymeric Delivery Systems 
In order to develop an efficient controlled-release system for therapeutic drugs is important 
to understand the release mechanism and the physico-chemical processes that mostly 
influence the release kinetics. The mechanism of release is the rate limiting step or series of 
rate limiting steps that control the rate of drug release from a device until release is 
exhausted. The major release mechanisms include: diffusion, solvent penetration/device 
swelling, degradation and erosion of the polymer matrix or a combination of these 
mechanisms occurring on different time scales that leads to a more complex release process 
(17). In Figure 5 there are presented schematic representations of these individual release 
mechanisms. Many processes can influence the rate of drug diffusion and degradation 
kinetics, for example, polymer-drug interactions, drug-drug interactions, water absorption 
and pore closure. By knowing and understanding such processes we can easily control drug 
release mechanisms.  
 
Figure 5. Schematic of common release mechanisms (a) Diffusion (b) Polymer degradation and erosion and (c) 
solvent penetration and device swelling (17). 
Transport through the surface of the polymer usually happens when a drug loaded depot 
formulation comes in contact with the medium (aqueous solution) as drug on the surface of 
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the polymeric matrix can easily diffuse to the release medium (17). This mechanism is also 
called burst release, which is characterized, with a rapid release of API from the polymeric 
matrix in a short period of time. Diffusion is the random movements of molecules from an 
area of high concentration to an area of lower concentration. As exposure of the drug loaded 
depot formulations with release medium proceeds, drug is released progressively from the 
polymeric matrix to the release medium. The release of drug from the matrix could be slow 
(17). This might come due to the polymer which could be dense or that the “cracks” in the 
polymeric matrix are not big enough in order for the API to diffuse through it. The polymeric 
matrix degrades when its exposure to medium proceeds. The water (from the medium) 
hydrolyzes the polymeric matrix into soluble byproducts (i.e. oligomers and monomers) and 
such elements can accumulate in the center of the matrix. During this phase, the polymeric 
matrix falls apart leading to a fast release of the drug molecules which are originated from 
the center of the polymeric matrix (17). 
In the case of a biphasic release behavior as presented in Figure 6, the release during the 
phase I is related to an immediate burst release, when drug molecules close to the surface in 
contact with the aqueous medium diffuse for the outside of the device (Figure 7). After this 
fast drug release period, the release occurs slowly and during this lag phase (II) the device 
starts slowly degrading. During this phase the matrix is still dense and the pores formed by 
the diffusion of the drug are not big enough to release the API. Due to the accumulation of 
degradation products inside of the polymeric device the pH a decrease leading to an increase 
in the degradation rate due to the autocatalytic effect of the degradation products and at a 
certain point the device disintegrates releasing the remaining loaded drug. Such moment can 
be manipulated by engineering the polymeric materials in use. 
 
Figure 6. Schematic representation of a biphasic drug release kinetics. 
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Figure 7. Theoretical bi-phasic release of a drug from a bulk-eroding polymeric system (Adapted from (18). 
2.3. Hot-melt extrusion 
Hot melt extrusion (HME) technique was first introduced in the plastics industry in the mid-
nineteenth century to manufacture pipes (19). Since then, it has mainly been used in plastic, 
rubber and food manufacturing industry (20). Currently more than half of all plastic products 
on the market including, bags, sheets and pipes are manufactured via HME. Thus, various 
polymers have already been used to form different shapes for a variety of domestic and 
industrial applications (20).  This technology has proven to be a robust method for producing 
numerous drug delivery systems including granules, pellets, sustained release capsules and 
implants (19), and therefore it has also been found to be useful in the pharmaceutical 
industry (20). Hot melt extrusion can be globally defined as the process of converting a raw 
material into a finished product by forcing them through a die applying heat at the same time 
(21).  
Hot melt extrusion can be classified into two categories: ram extrusion and screw extrusion. 
Ram extrusion is an extrusion with a simple design and with a discontinuous operation (19). 
The process occurs with the positive displacement ram which generates high pressure to 
push materials through the die – process represented in Figure 8. Materials are heated in the 
cylinder until molten materials are obtained and subsequentially the material passes through 
a die to obtain the desired shape (19). The ram extrusion has limited melting capacity and 
poor temperature uniformity. The products obtained by ram extrusion have poor 
homogeneity when compared with products obtained by screw extrusion (19). 
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Figure 8. Schematic representation of a ram extruder (22) 
A screw extruder consists in three sections: feeding zone, transition zone and metering zone 
which is represented in Figure 9 A starting material is feed into the feeding zone. The 
material is prepared to be conveyed along the barrel (23). A solid plug from the feeding zone 
is transferred to the transition zone where it is molten, mixed and compressed due to friction 
between the mixture, barrel and rotating screw (23). The driving force for the extruded 
material is the friction on the surface of barrel (23). During the process is necessary to apply 
heat that can be supplied by two sources: shearing of the rotating screw and electrical 
heating (19). The material reaches the metering zone in the form of a molten uniformly 
mixture, this zone acts like a flow reducer and a controller of the outcome rate (23). 
 
Figure 9. Schematic representation of screw hot melt extruder in a horizontal view (22) 
The screw extruders can be classified as single screw and twin screw extruders (20). The 
single screw extruder is a simple equipment formed by a screw rotating inside a barrel which 
is used for solid transportation, melting, mixing and pumping (19). A barrel convers the screw 
and contains three or more heating zones to elevate temperatures at the screw and barrel 
until meeting the desirable temperature. Pressure inside the barrel is generated by melting 
and mixing viscous materials and pumping them through a die (19). Twin screw extruders 
consist in two screws inside a barrel side by side (20). The use of two screws makes the 
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equipment more versatile once the direction of screw rotation can be changed (22). The two 
screws can either rotate in the same direction or can rotate in different directions (19). 
The transport mechanism and the mixing ability are the main differences between the single 
screw extruder and twin extruder (22). In a single screw extruder the transport mechanism is 
based on frictional forces in the solid conveying zone and viscous forces in the melt 
conveying zone. When compared with twin screw extruder the single screw extruder exhibits 
poor mixing capacity. In a twin screw extruder the mixing occurs both at a macroscopic level, 
where the material is exchanged from one screw to another, as well as at the microscopic 
level, where the mixing occurs at the high-shear regions of screw elements interactions (22). 
The use of twin screw extruder offers several advantages when compared to single screw 
extruder once in the first one the residence times are shorter, the process of melting is more 
stable and to achieve the equivalent output smaller equipment is required (22). 
When compared with conventional methods, hot melt extrusion offers several benefits, some 
of them are represented in Table 2. 
Table 2. Advantages of hot-melt extrusion (Adapted from (24). 
Feature Benefit 
Solvents not required Environmentally friendly, economical; No 
residual solvent in final product 
Continuous process Fewer unit batches required; Efficient scale-
up 
Intense mixing and agitation achieved Improved content uniformity 
Compressibility not required Useful for powders with low compressibility 
index 
Polymers serve multiple purposes Less number of excipients required; Cost 
effective 
Greater thermodynamic stability than 
that produced by other hot-melt 
methods 
Less tendency towards recrystallization 
The extrusion is a continuous method and the extruders can be used for mixing, melting and 
extrusion or reacting materials and this can be processed in a single operation unit (22). It is 
an anhydrous and solvent less process, which avoids the hydrolysis of the materials being 
used and also decreases the toxicity of the final product once there is no remaining toxic 
solvent (22). 
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2.4. Protein Stabilization 
The use of proteins as pharmaceutical drugs is becoming increasingly important to treat 
several diseases and disorders (25). Usually proteins are obtained in aqueous solution, 
however, many of them are unstable in aqueous medium which reduces their potential shelf 
life (25). These problems can be easily overcome by drying the protein however, during the 
drying processes, e.g. freeze drying, spray drying, the protein is subjected to harsh 
conditions through which its activity can be severely reduced. Thus, it’s necessary to add 
protective agents to prevent the adverse and sometimes irreversible effects of drying 
processes (25). 
Sugars can be used as protective agents for proteins during drying and storage. During 
drying, the water molecules surrounding the proteins are gradually replaced by sugar 
molecules. Being a polyol, the sugar molecules form multiple external hydrogen bonds with 
the protein by which structural integrity of the protein is maintained (25). The crystallization 
of the sugar should be low once the crystallization is accompanied by phase separation 
through which the interaction of the sugar molecules with the protein and thereby the 
protection is lost (25). It is essential that the sugar remains in the glassy state during 
handling and storage (Tg above room temperature) since the molecular mobility in this state 
is extremely low which makes the protein immobilized in the glass. This immobilization also 
protects the protein against degenerating effects after the drying process. The restricted 
molecular mobility disables some crystallization of the sugar for long periods of time. On the 
other hand, at temperatures above Tg, the mobility increases and the sugar protection is 
partially lost (25). The increase in the molecular mobility caused by higher temperatures also 
induces rapid crystallization of the sugar (25). 
The Tg of a sugar glass depends on the nature of the sugar and on the water content. Water 
acts as a plasticizer and the uptake of water by the sugar results in a strong decrease of the 
Tg (25). 
Sugars must be non-reducing agents since the reducing groups can react with amine groups 
of the protein and such reactions, which are the first of a cascade of reactions – Maillard 
reaction, can severely affect the protein activity (25). 
When freeze drying is used as a drying process it is preferable to use sugars with high Tg 
because the sample temperature should remain below the Tg. When the temperature is 
above the Tg, the freeze concentrated fraction is in the liquid or rubbery state thus the 
mobility is high. Furthermore, the protein concentration in the freeze drying fraction is high, 
therefore the degradation rate will increase when compared to the starting solution. 
Moreover, the sugar concentration is very high and crystallization can easily occur. 
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Additionally, freeze drying above the Tg results in a collapsed cake while below the Tg results 
in a porous cake. The last one is preferred because it can be easily reconstituted or 
processed (25). 
The oligosaccharide inulin is a potent lyoprotectant, since it holds physiochemical properties 
which are essential for any stabilizing agent, such as high Tg, low number of reducing groups 
and low crystallization rate. In the literature inulin sugars have already been successfully 
used for the stabilization of proteins (26). 
Biphasic Controlled Release of API’s from Biodegradable Implants 
Materials and Methods 15 
3. Materials and Methods 
3.1. Materials 
3.1.1. Chemicals used 
Table 3. Chemicals used in the different experiments and solutions preparations. 
Chemical Purity/Type Supplier MS# 
Acetonitrile Ultra LC-MS Actu-All chemicals 423 
Dichloromethane 
99.5% purity, 
stabilized with ethanol 
Acros organics 131 
Dioxane 99% purity, stabilized Acros organics 422 
Di-sodium Hydrogen 
orthophosphate  
anhydrous Fisher Scientific 169 
Potassium hydrogen 
orthophosphate 
>99% purity Fisher Scientific 168 
Sodium Azide 99% purity Acros organics 282 
Sodium Chloride >99% purity Merck 166 
Potassium Chloride >99% purity Fisher Scientific 167 
Protein X  RuG N.A 
Stabilized Protein X 9% RuG N.A 
InX 
Spray-dried, protein 
X:Inulin ratio 1:10 
RuG N.A 
Trifluoroacetic acid  Millipore 159 
Ultra-pure water  
RO, Ultra filtrations, 
UV, 0,22 μm filtered, 
resistivity = 18,2 
MΩ.cm at 25°C 
Innocore N.A 
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3.1.2. Equipment used 
Table 4. Equipment used for all the experiments and solutions preparation. 
Equipment Supplier/Type INN# / MS# 
2-decimal balance Kern 2010/015, 2009/027 
4-decimal balance Mettler Toledo 2011/025 
5-decimal balance Mettler Toledo 2013/021, 2011/006 
Centrifuge Thermo Scientific 2013/002 
Conveyer belt Thermo scientific 2009/038 
Digital thermoregulator VTF 2010/012 
Extruder 




Zirbus technology, Sublimator 
2x3x3/5 
2009/007 
Heating magnetic stirrer VELP SCIENTIFICA, Arex.X 2011/011 
Manifold Millipore 2011/035 
Oven (37 C) Hermeus 2004/007 
SEM JEOL, Neoscope 2011/039/A 
pH apparatus inoLab 2012/025 
UPLC Waters, Acquity 2010/002 
UPLC column 
Acquity C4 BEH peptide 
separation column ; 1.7 µm, 
2.1x50mm ; Waters 
N.A 
Vacuum pump Millipore 2011/036 
Vacuum oven Fistreem 2011/028 
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3.1.3. Disposable materials used 
Table 5. Disposables used during the experiments. 
Disposable Supplier/Type MS# 
Membrane filters Millipore, Durapore, 0.45 µm 347 
UPLC plate  Millipore 373 
3.1.4. Polymers used 
Table 6. Polymers used in the implant formulations. 
Composition Batch# IV (dL/g) Tg (°C) Tm (°C) 
30CP15C20-C40 RCP-1206 0.76 -60.1 51.7 
Poly (D,L Lactide) Purasorb® PDL 02 0.20 34-39 - 











0.20 40-45 - 
3.2. Solutions and buffers 
3.2.1. Phosphate buffer (100mM, pH 7.4) 
The components present in Table 7 were quantitatively added to 900 mL of UP water and 
dissolved using a stirring bar. After the components were dissolved, the solution pH was 
measured and adjusted when necessary with 1 M NaOH or 1M HCl until a pH of 7.4 ± 0.05 
was reached. The stirring bar was then removed and UP water was added in order to have a 
final volume of 1000 mL. After measuring the pH and adjust it to 7.4 ± 0.05, the buffer was 
filtrated with a 0.2 µm polyester (PES) filter. 
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Table 7. Amount of the different chemical products added to the UP water for the Phosphate buffer (100mM,pH 7.4) 
preparation. 
Chemical Amount  
KH2PO4 2.48 g ± 0.05 g 
Na2HPO4 11.61 g ± 0.1 g 
NaN3 0.20 g ± 0.05 g 
1 M NaOH For pH adjustment 
1 M HCl For pH adjustment 
UP water Add to 1 L 
3.2.2. Phosphate buffer (5mM, pH 7.0) 
The components present in Table 8 were quantitatively added to 900 mL of UP water and 
dissolved using a stirring bar. After the components were dissolved, the solution pH was 
measured and adjusted when necessary with 1M HCl until a pH of 7.0 ± 0.05 was reached. 
The stirring bar was then removed and UP water was added in order to have a final volume 
of 1000 mL. 
Table 8. Amount of the different chemical products added to the UP water for the Phosphate buffer (5mM,pH 7.0) 
preparation. 
Chemical Amount  
Na2HPO4 0.514 g ± 0.05 g 
NaH2PO4 0.330 g ± 0.05 g 
1 M HCl For pH adjustment 
UP water Add to 1 L 
3.3.3. Phosphate Buffer Saline (10mM,pH 7.40) 
The components present in Table 9 were quantitatively added to 900 mL of UP water and 
dissolved using a stirring bar. After the components were dissolved, the solution pH was 
measured and adjusted when necessary with 1M HCl until a pH of 7.4 ± 0.05 was reached. 
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The stirring bar was then removed and UP water was added in order to have a final volume 
of 1000 mL. 
Table 9. Amount of the different chemical products added to the UP water for the Phosphate buffer (10mM,pH 7.0) 
preparation. 
Chemical Amount 
NaCl 8.00 g ± 0.10 g 
KCl 0.20 g ± 0.05 g 
KH2PO4 0.24 g ± 0.05 g 
Na2HPO4 1.15 g ± 0.05 g 
NaN3 0.20 g ± 0.05 g 
3.3. Preparation of freeze-dried inX 
To obtain an aqueous inulin solution of 50 mg/mL, 6.847 g of inulin was dissolved in 138 mL 
of 5mM phosphate buffer solution (pH=7.0) under continuous heating in a hot plate (80oC) in 
a container closed with parafilm. After complete dissolution of inulin, it was allowed to cool 
down to room temperature (20oC). Finally, 568 mg of protein X was gently dissolved in 110 
mL of the inulin solution resulting in a protein concentration of 5 mg/mL. 
The solution of inulin and protein X was frozen and freeze dried (Zirbus technology, 
Sublimator 2x3x3/5) overnight according to the procedure described in Table 10. 
Table 10. Freeze-drying program. 
Step Phase Time (min) Temperature (oC) Vacuum (mbar) 
01 Freeze 10 -45 -- 
02 Freeze 60 -45 -- 
03 Dry 60 -45 30 
04 Dry 240 -5 0.220 
05 Dry 480 -5 0.220 
06 Dry 120 10 0.055 
07 Dry 60 10 0.055 
08 Dry 60 25 0.055 
09 Dry 20 25 0.055 
10 Dry Until removal of the sample 20 0.001 
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3.4. Implants formulation 
3.4.1. Biphasic release implants prepared by Hot-melt extrusion 
Hot melt extrusion was performed using a HAAKE Mini Lab II from Thermo Scientific co-
rotating twin-screw extruder equipped with conveyer belt to stretch the molten material. The 
extrusion was performed with a fixed screw speed of 10-15 rpm. 
The powder blend was prepared manually by mixing the core mix with the polymer in 
different ratios. The core mixture was composed by protein X, inulin and mannitol. In Table 
11 is presented the extent of the experiments performed during this work where the 
influence of several variables has been evaluated. 
For the PDL 02 implants, the polymer was grinded in a mortar and then sieved in order to 
collect the fraction with particle sizes below 180 µm. For the other materials, the grinding 
step was performed with a kitchen grinder and dry ice. The final material was dried on the 
vacuum oven overnight and then sieved to collect the fraction with particle sizes below 180 
µm. The selected polymer was then mixed with the core mixture in a mortar for 
approximately 10 minutes. Afterwards, the mixture of polymer and protein was fed to the 
extruder and the implants with different diameters (0.6, 1.0 and 1.4 mm) were finally 
collected. 
A cylindrical die of 1.5 mm was used to modify the diameter of the implants by changing the 
speed of the conveyer belt. The extruded samples were stored in a freezer at -20oC until 
further analysis. 
In order to understand the biphasic release kinetics from extruded implants several 
parameters need to be analyzed. Implant diameter, ratio between core material and polymer, 
presence of mannitol, particle size of protein used and polymer composition were all 
considered the critical formulation parameters. 
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JA1408 PDL 02 1:10 Protein X 1:10:14 70 
JA1410 PDL 05 1:10 Protein X 1:10:14 75 
JA1416-01 PDL 02 1:10 inX (SD) 1:10:14 70 
JA1416-02 PDL 02 1:10 inX (SD) 1:10:0 70 
JA1424-01 PDL 02 1:10 inX (FD) 1:10:0 70 
JA1424-02 PDL 02 2:10 inX(FD) 1:10:0 70 
JA1430-02 PDL 02 3:10 inX(FD) 1:10:0 70 
JA1434 PDLG 5002 1:10 inX (SD) 1:10:0 50 
JA1452 30CP15C20-C40-7 1:10 inX (FD) 1:10:10 50 
3.5. Implants characterization 
3.5.1. Surface morphology 
Scanning electron microscopy (SEM) is based on the incidence of a beam of accelerated 
electrons on the sample. These accelerated electrons interact with the sample, exciting its 
atoms which emit secondary electrons. According to the angle between the primary beam 
and the surface of the sample, it is possible to detect and analyze the surface topography. 
In order to evaluate the surface morphology of the developed implants, SEM was performed 
using a Neoscope, Jeol. The sample was first placed in the carbon conductive tape and 
subsequently coated with a thin gold layer (3 minutes coating time). The sample was then 
introduced in the microscope, vacuum was applied and the implants were imaged using a 10 
kV electron beam. 
3.6. In Vitro release study 
For the In vitro release (IVR) study, approximately 40 mg of each implant was transferred to 
a 2mL plastic tube (N=3). Then, 2 mL of release buffer (100 mM Phosphate buffer, pH 7.4) 
was added to the same tube, which was closed with the screw cap and placed in the oven at 
37oC. 
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Samples were taken at the beginning of the IVR study and after 3h and 1, 2, 3, 4, 7, 14, 21, 
28 days (or until complete release was observed).  Afterwards, 2 x 0.9 ml of the supernatant 
was transferred to sample tubes: one to analyze by Ultra performance liquid chromatography 
(UPLC) and other to keep in the freezer. In order to refresh the release buffer and restore the 
original volume, 1.8 ml of fresh buffer was added to the original plastic tube. 
3.7. Quantification of protein X by Ultra Performance Liquid 
Chromatography 
Ultra Performance Liquid Chromatography (UPLC) is a chromatographic technique that allows 
the identification and quantification of chemical compounds. This technique was used to 
determine the amount of protein X released from the implants. Table 12 presents the UPLC 
method to measure protein X released from the implants. 
Table 12. UPLC method to measure Protein X 
Eluent 
A : 0.025% Trifluoroacetic Acid (TFA) in 
water 
B : 0.025% TFA in ACN 
Flow 0.7 mL/min 
Injection volume 10 µL 
Number of injections 2 
Sample temperature 4°C 
Run time 5 min 
Gradient 
0 min : 30% B 
0-3 min : 30% to 60% B 
3-3.01 min : 60% to 90% B 
3.01 to 4 min : 90% to 30% B 
Column 
Acquity C4 BEH peptide separation column ; 
1.7 µm, 2.1x50mm ; Waters 
Column temperature 50°C 
Detection UV, 213 nm 
The UPLC analysis was performed using 200 µL of sample in a 96-well plate. Samples and 
standards were filtrated through a 96 well filter plate with 0.2 µm pore PVDF filter prior to 
measurement. For the standard preparation, protein X (coarse) was used. First, a stock 
solution with a concentration of 1000 µg/g was prepared by dissolving 20 mg of protein X in 
20 g of 10mM PBS, pH 7.4. The stock solution was diluted to desirable concentrations (5 -250 
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µg/g), as listed in Table 13. Standards were labeled and stored at 4°C for a maximum period 
of 1 month.  
Table 13. Dilutions used to prepare protein X standard solutions from a 1000 µg/g stock solution. 
Standard 












1 1.00 3.00 250.00 
2 0.80 3.20 200.00 
3 0.60 3.40 150.00 
4 1.30 11.70 100.00 
 




5 3.00 1.00 75.00 
6 2.00 2.00 50.00 
7 1.00 3.00 25.00 
8 1.30 11.70 10.00 
 




9 2.00 2.00 5.00 
10 0.00 4.00 0.00 
Low concentrations are also measured in order to determine the Limit of detection (LOD) and 
the Limit of quantification (LOQ) of protein X by UPLC. The determination of these values is 
important in order to know the lowest concentration of protein that could be detected and 
differentiate from a blank by the UPLC (LOD) and the lowest concentration of protein that 
could be reliably quantify by UPLC (LOQ). To do this, 7 standards from 0 to 12 µg/g of 
protein X are measured via UPLC.  The LOD and LOQ are calculated via regression analysis, 
and by using the formulas below. 
𝑺𝒕𝒂𝒏𝒅𝒂𝒓𝒅  𝒅𝒆𝒗𝒊𝒂𝒕𝒊𝒐𝒏 ∶ 𝑺𝑫 = 𝒚!𝒚! 𝟐𝒏!𝟐                                  Equation 1 
  𝑳𝑶𝑫 = 𝟑.𝟑∗𝑺𝑫𝑺𝒍𝒐𝒑𝒆                                                          Equation 2 
    𝑳𝑶𝑸 = 𝟏𝟎∗𝑺𝑫𝑺𝒍𝒐𝒑𝒆                                                 Equation 3 
 
The slope is determined via regression analysis of the validation line. The variables y and y’ 
correspond to the experimental response and the calculated response of the samples and n 
corresponds to the number of points measured. 
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3.8. Content determination 
For the characterization of the implants, a content determination method is necessary in 
order to determine the real loading of protein X.  
For content determination study 80 mg of implants were dissolved in 5 mL of ACN in order to 
dissolve the polymer and then extract the drug from the polymeric device. After complete 
dissolution of the polymer, the solution was centrifuged at 12000 rpm for 10 min. 4.8 mL of 
supernatant was removed and 4.8 mL of 100mM Phosphate buffer, pH 7.4 was added in 
order to dissolve the API. After completely dissolution of the protein in the buffer the samples 
were analyzed by UPLC.  
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4. Results and Discussion 
4.1. Detection and Quantification of Protein X by Ultra Performance Liquid 
Chromatography 
The UPLC method described in the previous section leads to a chromatogram identical to the 
one presented in Figure 10. 
 
Figure 10. Chromatogram obtained by the UPLC method described in the Materials and Methods section. 
From the chromatogram represented in Figure 10 it is possible to observe that the protein X 
peak is clear and separated from the other peaks. This makes possible to quantify the area of 
this peak and to obtain a calibration line, which allows the creation of a direct relation 
between protein concentration and peak area. 
 
Figure 11. Schematic representation of calibration lines used for UPLC measurements.  
In Figure 11 several calibration curves used for the protein X quantification are represented. 
These calibration lines present a high linearity and low deviation between different calibration 
series, which indicates that the UPLC method is reproducible. The limit of detection (LOD) 
and the limit of quantification (LOQ) for the method were estimated and the results are 
present in Table 14. 
A = 9156.7Cx - 12002 
R² = 0.9999 
A = 9218.9Cx- 16015 
R² = 0.9998 
A = 8708.4Cx - 11855 
R² = 0.9999 
A = 9213.9Cx - 12369 












Protein X Concentration (Cx) (µg/g) 
X 
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Table 14. Limit of quantification and limit of detection of protein X via UPLC 
LOD 0.4 µg/g 
LOQ 1.2 µg/g 
The protein X presence on samples could be detected by the UPLC starting from a 
concentration of 0.4 µg/g and its quantification is reliable starting from 1.2 µg/g. 
4.2. Surface morphology analysis of the implants 
4.2.1. Effect of the material 
Figure 12 shows the differences in the surface morphology of implants made with different 
polymers, when all the remaining characteristics were unchanged. The surface of the implant 
prepared with PDL 02 is rougher and implants made with PDL 05 present some flow lines on 
the surface. PDL 05 has a high molecular weight thus, presents a higher melt viscosity and 
flows less when compared with formulations with PDL 02. This higher melt viscosity leads to 
the formation of lines on the surface when the melt flow exits the die. 
 
Figure 12. Scanning electron micrographs of implants made of (A) PDL02 (JA1408) and (B) PDL05 (JA1410). 
4.2.2. Effect of the protein particle size 
Protein stabilization via freeze-drying leads to bigger particle sizes when comparing to the 
ones obtained from stabilization via spray drying. Both SEM pictures present in Figure 13 
were prepared with the same drug loading and without mannitol. In Figure 13 (A) is 
represented a formulation with spray-dried protein X while in Figure 13 (B) is an implant 
loaded with freeze-dried protein X. The formulation prepared with freeze-dried protein offers 
a rougher surface when compared with the same formulation with spray-dried protein. For 
this situation the protein particles are dispersed in the viscous polymeric flow, thus, if the 
particles are big a rough surface will be formed. 
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Figure 13. Scanning electron micrographs of implants made with (A) Spray-dried (JA1416-02) and (B) Freeze dried 
(JA1424-01) stabilized protein. 
 4.2.3. Effect of the drug loading 
All formulations present in Figure 14 were made with PDL02 and with a core mixture with 
freeze-dried stabilized protein. The increase of drug loading leads to rougher implants. During 
extrusion the protein remains in the solid state dispersed in the viscous polymeric flow. 
However, as the material leaves the extruder, polymer tends to solidify and the solid particles 
remain in the matrix. The ones closer to the surface are finally responsible for the visual 
roughness of the implant. 
 
Figure 14. Scanning electron micrographs of implants with a ratio of (A) 1:10 (JA1424-01), (B) 2:10 (JA1424-02) and 
(C) 3:10 (JA1430-02) core mixture: polymer. 
4.2.4. Effect of Mannitol 
The presence of mannitol in the core mixture as a stabilizing agent has a huge effect on the 
surface morphology of the implant (Figure 15). Both formulations present in Figure 15 were 
prepared with protein stabilized by spray drying which produces small particle sizes. During 
the process of extrusion the mannitol particles remain dispersed in a solid state which leads 
to an irregular surface when compared with a formulation without mannitol.   
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Figure 15. Scanning electron micrographs of implants (A) with mannitol (JA1416-01) and (B) without mannitol 
(JA1416-02) in the formulation. 
 
4.3. In vitro release study of the implants 
In order to understand the release mechanism of the extruded implants with different 
settings an in vitro release study was performed following the procedure present in the 
Materials and Methods section. The main objective of this work was the studying of the 
parameters that can influence the biphasic release kinetics of a hot melt extruded implant 
therefore, an in vitro release study is relevant.  
4.3.1. Parameters influencing burst release 
In Figure 16 is presented the influence of the implant drug loading on the burst release and 
the result shows that there is no big difference between the implants loaded with a ratio of 
1:10 and 2:10 core mixture:polymer. Low loadings result in low burst and low plateau level, 
below 10%. On the other hand, the increase of drug loading results in a more sustained 
release kinetics and an increase of total protein released over the same period of time. When 
an implant loaded with high loading starts releasing the drug, even for small drug particles, 
more pores are formed in the implant structure. Furthermore, the presence of inulin as a 
lyoprotectant in the matrix of the polymeric device can help in the formation of pores. With 
higher loadings there are more particles, containing both drug and inulin, closer to each other 
which means that sugar particles can be connected. Once in contact with water sugar 
dissolves and pores are easily formed which can severely influence drug release profile. With 
this porous matrix it is easier for the drug to diffuse for the release medium. To find the 
desired release kinetics in terms of burst release other ratios between the core mixture and 
the polymer can be tested. Furthermore, the batch with a ratio of 2:10 should be repeated 
and consolidated as the tendency once increasing drug loading seems to be an incremental 
cumulative drug release which does not happen when comparing ratio 1:10 and 2:10. 
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Figure 16. Schematic representation of release kinetics of different loaded implants. 
The state of the protein used for the implants preparation has a huge difference on burst 
release (Figure 17). Using non-stabilized protein leads to a higher burst release and a higher 
plateau level when compared with the stabilized proteins. Burst release is often associated to 
the proteins present in the implant surface. For bigger particles, like the non-stabilized 
protein particles the burst must be higher because when the surface proteins diffuse to the 
medium big pores are formed that can be connected allowing the protein inside to diffuse for 
the release medium. The stabilized proteins have a smaller particle size therefore, the 
molecular diffusion is slower and the formed pores are smaller therefore, it is more difficult to 
have connected pores inside of the implants which would lead to a higher burst release. 
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Figure 18 presents in vitro release kinetics for different polymers. The formulations prepared 
with PDL 05 have a higher burst release when compared to the other formulations. This 
polymer has a Tg between 42-47 ºC thus, at release temperature (37ºC) the implants 
prepared with this polymer are below Tg, the molecular mobility is low and the pores in the 
formulation are open. On the other hand, the Tg of PDL 02 is between 32-37ºC thus, at 
release temperature they are above Tg, the material is in a rubbery state and the pores 
which could be present in the material will probably close.  
 
Figure 18. Schematic representation of IVR kinetics from implants with different materials. 
4.3.2. Parameters influencing on set and slope of secondary pulse 
Huge differences can be observed in the release behavior of PDL-based formulations when 
comparing to PDLG-based formulations (Figure 19). Since the drug release from the implants 
is degradation-dependent, polymer degradation kinetics play an important role on the drug 
release behavior. Co-polymerization of poly-lactic acid with glycolic acid reduces the 
crystallinity of the polymer and increases the ability of water to penetrate the matrix 
compared with pure poly-lactic acid. Therefore, such co-polymer gave rise to a faster 
degradation ratio compared to PDL-based materials when compared to a faster drug release 
which is generically obtained from the implants containing glycolic acid. Additionally, the 
presence of glycolic acid in the co-polymer leads to a higher accumulation of acidic products 
inside of the implant, which accelerates the polymer degradation even more and also justifies 
the faster drug release. This effect may also be responsible for the sharper pulse of the PDLG 
materials. With 20CP15C20-C40 we are expecting a low swelling degree thus, a slower 
degradation however, until now, is not possible to conclude anything from the release 
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Figure 19. Schematic representation of IVR kinetics from implants prepared with different polymer grade. 
There was a huge effect induced by the state of the protein used with the second pulse 
(Figure 17). When the polymer starts degrading more pores will be formed which allows the 
protein to diffuse for the outside of the device. As bigger and bigger particles leave the 
device throughout time, more and more pores are formed which induces easier connections 
between pre-existing pores and a consequent easier diffusion of the protein to the external 
environment. As it happens with burst release behavior, the diffusion of smaller particles will 
create smaller pores thus, it is more difficult to have connections between the pores. 
Since the polymer degrades by hydrolysis, a slower degradation is expected for a larger 
implant diameter (22). In accordance, also slower drug release kinetics is expected from 
larger implants. Actually, implants with larger diameters offer a longer diffusion distance of 
the immobilized drug once the pore size has been increased by polymer degradation and 
allows drug release to the external environment (22). An identical rational is also valid for the 
entrance of water which will induce polymer degradation. In practice, from the present study 
there was no significant difference between 1.0 and 1.4 mm implants. However, a small 
difference is observed for the smaller implants (0.6 mm) when comparing to the larger ones, 
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Figure 20. Schematic representation of IVR kinetics from JA1408 implants with different diameters.	  	  
The presence of mannitol has no effect on burst release however, a small effect is observed 
in the slope of the secondary pulse. Mannitol is a fast dissolving sugar thus, it was expected a 
higher release since the dissolution of the sugar will be responsible for the pore formation 
and the drug could diffuse for the outside of the device. 
	  
Figure 21. Schematic representation of IVR kinetics from implants with and without mannitol. 
Hot melt extrusion is a process that allows the production of implants with a bi-phasic 
release. Changing the polymer from PDL 02 to PDL 05 leads to an increase in the burst 
release. PDL 02 based formulations loaded with spray dried or freeze dried inX shows a low 
burst release (less than 5%), hardly any release between burst and secondary release pulse, 
second release pulse starts after 35 days, although the slope of the pulse is not as sharp as 
initial requirements for a biphasic drug release. Using polymers with glycolide in the 
composition leads to a shorter lag phase and to an increase in the slope of the secondary 
pulse. Theoretically, larger implant diameters lead to a slower drug release however, the 
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4.4. Incomplete protein X release - Discussion 
From the release kinetic analysis it is possible to observe that after a second release pulse 
there is a plateau level. Therefore, is important to understand if the protein was lost during 
the release or if protein was still remaining inside of the implant. A root analysis was made to 
understand in which steps the protein was lost. For that, a flowchart (Figure 22) with the 
possible critical parameters was created and an analyse to those parameters was made. 
 
Figure 22. Flowchart of preparation of protein X loaded extrudates. 
4.4.1. Protein X losses during manufacturing process 
To perform a detailed characterization of the implants a content determination method is 
necessary to quantify the exact protein X loading. Additionally, such analysis also allows to 
the amount of protein lost during manufacturing process. Both parameters are represented in 
Table 15. 
Table 15. protein X content of the implants after manufacturing process. 















JA1408 PDL02 Coarse X 70 0.36 0.23 35 
JA1410 PDL05 Coarse X 75 0.36 0.19 44 
JA1416-01 PDL02 inX (SD) 70 0.0585 0.581 0.6 
JA1416-02 PDL 02 inX (SD) 70 0.81 0.61 24 
JA1424-01 PDL02 inX (FD) 70 0.82 0.75 8 
JA1424-02 PDL02 inX (FD) 70 1.47 0.85 42 
JA1430-02 PDL02 inX (FD) 70 2.08 1.90 8 
JA1434 PDLG5002 inX (SD) 50 0.84 0.61 27 
JA14523 30CP15C20-C40 inX (FD) 47 0.29 0.22 23 
During the manufacturing process protein losses from 8% to 44% were detected and the 
variation inter-batch is very significant even for similar batches. Thus protein losses cannot be 
easily associated with specific process parameters or materials used. Although, in general 
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terms, batches using non-stabilized protein (coarse X) gave rise to higher protein losses when 
comparing to batches using stabilized proteins, which clarifies the utility of inulin. After the 
analysis of these results, the similar behavior of JA1424 implants is justified by the similar 
loading of both. 
Several parameters can influence the loss or denaturation of protein during the 
manufacturing process: the protein stabilization with inulin, the physical mixing in the mortar, 
the temperature and the shear stress during extrusion. In order to understand and identify 
the critical steps which mainly influence protein stability all of the parameters were studied 
excepting the effect of shear stress since it would represent a prohibitive spending of protein 
due to the minimum loading amounts on the extruder equipment in use. 
The exact loading of the stabilized protein in inulin is represented in Table 16. According to 
the data collected, independently of the batch, the difference between the theoretical loading 
and the real loading is not significant (<2%), thus, we assume that the stabilization process 
is not detrimental for the protein. 












NG14B03A SD 8.44 8.48 < 1% 
JA1451 FD 9.49 9.34 1.4% 
In order to evaluate the effect of polymer, protein and inulin mixture using a mortar, all the 
components were mixed for 10 minutes and protein was quantified via UPLC to detect the 
percentage of protein losses in the process. 










JA1458-02 0.35 wt.% 0.31 wt.% 13% 
According to Table 17 more than 10% of protein is lost during the physical mixing, which can 
be caused by the formation of aggregates or adsorption to mortar. Changing the porcelain 
mortar to an agate mortar which has a smoother surface could be a good alternative 
approach to overcome the protein losses during physical mixture. 
To verify the effect of the temperature in protein stability, the protein was exposed to 50oC 
and 75oC during 5, 10 and 15 minutes, these times represent an approximation to the 
residence time of the protein inside of the extruder. And the temperatures were chosen 
taking into consideration maximum and minimum temperatures used during extrusion 
process. 
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Figure 23. Schematic representation of remaining non-stabilized protein X after heating exposure. 
Figure 23 shows the amount of remaining protein after 5, 10 and 15 minutes at 50ºC or 
75ºC.  As the protein is stable at these temperatures, the temperature effect seems not to be 
a detrimental factor for the protein loss or denaturation during extrusion. Therefore, we 
conclude that the shear forces inside of the extruder and the physical mixing step may 
represent the main causes for protein loss during the extrusion. 
4.4.2. Protein X losses during in vitro release 
From the release kinetic analysis it is possible to observe that after a second release pulse 
there is a plateau level. Therefore, in order to understand if the protein was lost during the 
release or if protein was still remaining inside of the implant, a determination of the drug 
content in the implants was made. The results are present in Table 18. 











JA1408 PDL02 Coarse  30 % < LOD 
JA1410 PDL05 Coarse  20 % < LOD 
JA1416-01 PDL02 inX (SD) 65 % < LOD 
JA1416-02 PDL02 inX (SD) 86% < LOD 
JA1424-01 PDL02 inX (FD) 80 % < LOD 
JA1424-02 PDL02 inX (FD) 50 % < LOD 
JA1430-02 PDL02 inX (FD) 27 % < LOD 
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As no remaining protein X was found inside of the implants after content determination we 
hypothize that an irreversible interaction between protein X and the polymer and/or an 
interaction between the protein and polymer degradation products may be occurring. 
4.4.2.1. Interaction between protein X and the polymer. 
To determine if the contact between the protein and the polymer is detrimental to the protein 
a solution with a target concentration of protein was incubated with 3 different polymers: 
PDL 02, PDLG 5002 and Poly-ε-caprolactone for four days at 37ºC and the decrease in 
protein concentration was analyzed. The maximum protein loss was 5% so we can assume 
that the interaction between the protein and the polymer is not a main factor for the protein 
loss during in vitro release. 
 
Figure 24. Protein X concentration after four days incubated with PDL 02. 
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Figure 26. Protein X concentration after four days incubated with Poly- ε -caprolactone. 
4.4.2.1. Interaction between protein X and product degradation products 
To analyze the effect of degradation products in the stability of protein X, a protein solution 
was mixed with 2000 µg/g of a monomer solution containing D,L Lactide, Glycolide and ε -
Caprolactone. The mixture was then incubated at 37ºC for 14 days and the decrease of intact 
protein X concentration was analyzed. For non-stabilized protein incubated with D,L Lactide 
and glycolide solutions approximately 25% of the protein was lost while under similar 
conditions following incubation with ε -caprolactone just about 10% was lost. Such result 
may have occurred due to the more acidic climate created in the solutions composed by D,L 
lactide and glycolide monomers since the pH was close to 2 while for the ε -caprolactone 
solution was  about 3. For stabilized protein by freeze drying, 25% of protein was lost when 
was incubated with a D,L Lactide solution. For ε -caprolactone and glycolide solutions only 
10% of the protein was lost. The incubation of the stabilized protein by spray drying in ε -
caprolactone and D,L Lactide led to a loss of 25% of the protein while for the incubation with 
glycolide only 12% are lost. Based on the results obtained, we hypothesize that the 
stabilization of the protein using inulin is not effective in liquid state since the sugar will 
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Figure 27. Schematic representation of the amount of remaining coarse protein after incubation with monomers 
solutions. 
 
Figure 28. Schematic representation of the amount of remaining FD protein after incubation with monomers 
solutions. 
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In order to confirm whereas the protein is stable when exposed to low pH levels, three 
independent solutions of 20% wt of a single monomer (lactide, glycolide, ε -caprolactone) 
were prepared (monomers were hydrolyzed overnight at 50oC) to study their effect on the 
protein which was then added on the solid state. The three solutions represent acidic 
degradation products and before protein addition (target concentration of 200 µg/g) the pH 
of every solution was measured and adjusted to 3 using NaOH, as this pH level is close to the 
expected inside of implants under bulk degradation. When the protein was added, no 
dissolution was observed, probably as a result of the acidic climate which may have caused 
protein denaturated and formation of aggregates as Figure 30 illustrates. As the pH of the 
solution was close to the isoelectric point of the protein, besides the possible denaturation 
the dissolution of the protein also became more difficult. The isoelectric point is the pH of a 
solution at which the primary charge of a protein becomes zero. If the pH of the solution is 
above the isoelectric point the surface of the protein is negatively charged consequently, 
repulsive forces are predominant. On the other hand, if the solution pH is below the 
isoelectric point the protein surface is positively charged and repulsion between molecules 
will also occur. However, when the solution has a pH close to the isoelectric point of the 
protein, positive and negative charges will cancel and, therefore, repulsive electrostatic forces 
are reduced and the attraction forces become more predominant. Ultimately, such attraction 
forces may cause aggregation and precipitation as detected during the current experiment. 
 
 
Figure 30. Visual aspect of monomer solutions with protein X. 
At low pH the protein takes on a molten globular for min which flexibility of the side chain is 
increased decreasing stability and changes on the tertiary structure are observed (27).  
For all states of protein incubated with D,L Lactide and ε -caprolactone solutions about 98% 
of active protein was lost while after incubation with glycolide about 70% of protein in an 
active state was lost (Figure 32, Figure 33 and Figure 34). This experiment was a simulation 
of the behavior of the protein when in contact with degradation products inside of implants. 
Thus, the decreasing in the protein content is more evident than when the protein is 
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incubated with a solution with low concentration of monomers. This experiment justifies the 
incomplete release of the protein from the implants after the lag phase. In Table 18, it is 
possible to observe that from the batches with stabilized protein and with a ratio of 1:10 core 
mixture: polymer (JA1424-01, JA1424-02 and JA1434) the losses during the release are 
different. A small amount of protein is lost in formulations with PDLG when compared with 
PDL formulations. These results are in accordance with the results obtained by this 
experiment since the incubation with glycolide monomers has led to small losses during in 
vitro release. 
In the chromatogram it was possible to observe an additional peak which can be associated 
to the degraded protein. Furthermore, this peak tends to appear in the last measurements of 
the samples undergoing in vitro release studies which demonstrate an increasing 
susceptibility of the protein X to acidic environments. 
 
 
Figure 31. Chromatogram obtained for protein X incubated with Glycolide for 4 days. 
X 
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Figure 32. Schematic representation of the remaining amount of protein X after incubation with a 20%wt monomer 
solution. 
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Figure 34. Schematic representation of the remaining amount of FD protein X after incubation with a 20%wt 
monomer solution. 
Table 15 illustrates the variability of lost protein during in vitro release studies from batch to 
batch. The extrusion process requires higher temperatures to melt the polymer. After 
extrusion, the implant is a dense structure, consequently, during release it is more difficult 
the diffusion of the acid degraded products (22). The batches with smaller protein losses are 
the ones prepared with non-stabilized protein. As referred previously, with the diffusion of the 
protein out of the devices a porous structure is formed inside of the implant, which facilitates 
the diffusion of another drug molecules as well, the degradation products. On the other hand, 
for stabilized proteins with a low loading (JA1416, JA1429-01 and JA1429-02) the pores 
formed by the protein diffusion are not enough to allow the diffusion of the degradation 
products thus, they stay inside of the implant and it is formed an acidic microclimate which is 
detrimental for the protein. In the case of an implant with an higher loading like JA1430-02 
the mechanism is similar to the ones with non-stabilized protein, with the diffusion of the 
drug the structure became more porous and the diffusion of the degradation products is 
facilitated. 
JA1434 implants were prepared with PDLG, which is a faster degrading polymer due to the 
glycolide content thus a porous structure is easily formed when compared with PDL materials. 
However, the presence of glycolic acid in the medium is more detrimental to the protein (27). 
This effect is counteracted by the faster release of the drug thus, compared with the 
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5. Conclusions 
The objective of this work was to produce implants as a drug delivery system and to study 
the effect of several process parameters such as drug loading, polymer composition and the 
state of the protein to be released from implants. 
Hot melt extrusion is a process that allows the production of implants with a bi-phasic 
release. Changing the polymer from PDL 02 to PDL 05 leads to an increase in the burst 
release while using polymers with glycolide in the composition (PDLG-based co-polymers) 
leads to a shorter lag phase. The state of the protein also influences the release kinetics, for 
non-stabilized protein the burst release is higher when compared with stabilized proteins. 
Theoretically, larger implant diameters lead to a slower drug release however, the same logic 
was not clearly observed in the formulations prepared.  
The accumulation of acidic degradation products inside of the implant is crucial to obtain a bi-
phasic drug release. For this study, the protein used denatured during release, the 
accumulation of degradation products inside of the implant leaded to an acidic micro-
environment which is detrimental for the protein. At that low pH the protein loses the native 
conformation leading to a loss in the activity.Therefore, drugs which are highly sensitive to 
acidic environments seem not to be suitable for such therapeutic approach. 
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6. Future work and recommendations 
In order to further study and understand the mechanisms influencing bi-phasic release of a 
drug, an API stable at low pH should be used instead of protein X.   
During the manufacturing preparation, the porcelain mortar should be replaced for an agate 
mortar since the last one has a smother surface. This modification is expected to enhance 
mass yields, although after this replacement a batch of implants should be made to analyze 
the exact losses due to the shear forces applied. 
In incorporation of magnesium hydroxide in the formulation could help raising the acidic 
microclimate inside of the device allowing this type of devices to be a pH sensitive drug 
carrier. 
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